WILMINGTON, N.C., Feb. 17 /PRNewswire-FirstCall/ -- aaiPharma Inc.
(Nasdaq: AAII) announced today that it and certain officers of the Company
have been named as defendants in a shareholder class action lawsuit alleging
violations of federal securities law. The suit asserts claims under Sections
10(b) and 20(a) of the Securities Exchange Act of 1934, and alleges that these
violations took place between July 23, 2003 and February 4, 2004. aaiPharma
believes that these claims are without merit and intends to defend itself
vigorously.
About aaiPharma
aaiPharma Inc. is a leading, science-based pharmaceutical company focused
on pain management, with corporate headquarters in Wilmington, North Carolina.
With more than 24 years of drug development expertise, the Company is focused
on developing, acquiring, and marketing well-known, branded medicines in its
targeted therapeutic areas. aaiPharma's development efforts are focused on
developing improved medicines from established molecules through its
significant research and development capabilities. For more information on the
Company, including its product development organization AAI Development
Services, please visit aaiPharma's website at http://www.aaipharma.com .
SOURCE aaiPharma Inc.
 back to top
Related links:
http://www.aaipharma.com
CONTACT:
Media, Andrea L. Johnston, Vice President,
Corporate Communications, +1-910-254-7340, or Investors, James B.
Sloan, Jr., Senior Vice President, Corporate Finance,
+1-910-254-7690, both of aaiPharma Inc.
|
